Study on Using Dye-Vert Plus System to Reduce Kidney Injury in High-Risk Adults Undergoing Coronary Angiography or PCI

What this Trial Is About

Researchers are studying the risk of contrast-induced nephropathy CIN, a type of acute kidney injury, in high-risk patients undergoing coronary angiography CAG or percutaneous coronary intervention PCI. CIN occurs in 10% to 30% of these patients and is linked to factors such as advanced age, kidney disease, diabetes, dehydration, and the use of certain drugs. This study aims to evaluate how using the DyeVert Plus Contrast Reduction System along with a standard hydration protocol may impact the rates of acute kidney injury in these patients. The study compares two groups one receiving the standard hydration protocol alone and the other receiving the standard hydration plus the DyeVert Plus System. The DyeVert Plus System monitors and reduces the amount of contrast dye used during the procedure by displaying real-time contrast volumes and savings. This device is designed to minimize kidney exposure to contrast media during cardiac catheterization procedures. Participants will be monitored for acute kidney injury over three days following their procedure. Researchers will assess kidney function using measurements such as estimated glomerular filtration rate eGFR and serum creatinine. The study also evaluates contrast-related complications and the impact on hospital costs. This prospective trial involves both inpatient and outpatient adults aged 18 to 90 years with specific kidney function criteria, and participation duration includes pre-procedure hydration and post-procedure monitoring.

Single-Center Prospective Study to Investigate the Difference in the Incidence of Contrast-Induced Nephropathy in High-Risk Patients With the Use of the Dye-Vert Plus System